Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 10874687 Highly active compounds against COVID-19

Patent 10874687 was granted and assigned to Atea Pharmaceuticals, Inc. on December, 2020 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
Current Assignee
Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals, Inc.
Date Filed
September 10, 2020
Date of Patent
December 29, 2020
Patent Applicant
Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals, Inc.
Patent Application Number
17017443
Patent Citations
‌
US Patent 10239911 Beta-D-2′-deoxy-2′-alpha-fluoro-2′-beta-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
‌
US Patent 10000523 β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N
‌
US Patent 10005810 Process for preparing nucleoside prodrugs
‌
US Patent 10005811 β-D-2′-deoxy-2′-α-fluoro-2′β-C-substituted-2-modified-N
‌
US Patent 10519186 Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus
Patent Citations Received
‌
US Patent 12077498 C4-carboxylic acid-substituted tryptamine derivatives and methods of using
0
‌
US Patent 11446244 Compositions containing verteporfin, ribavirin, gemcitabine, or combinations thereof and methods of use for treating COVID-19, cancer, or non cancer diseases
‌
US Patent 11918598 Compositions containing Verteporfin, Ribavirin, Gemcitabine, or combinations thereof and methods of use for treating COVID-19, cancer, or non cancer diseases
0
‌
US Patent 12065404 C4-carboxylic acid-substituted tryptamine derivatives and methods of using
0
‌
US Patent 11690860 Treatment of HCV infected patients with cirrhosis
0
‌
US Patent 11707480 Highly active compounds against COVID-19
0
‌
US Patent 11746087 C4-carboxylic acid-substituted tryptamine derivatives and methods of using
‌
US Patent 11376232 Vidofludimus for use in the treatment or prevention of viral diseases
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
10874687
Patent Primary Examiner
‌
Patrick T. Lewis

Find more entities like US Patent 10874687 Highly active compounds against COVID-19

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo